Literature DB >> 17828536

Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer.

Sandip Basu, Abass Alavi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 17828536     DOI： 10.1007/s00259-007-0506-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  36 in total

1.  Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Authors:  K Spaepen; S Stroobants; P Dupont; J Thomas; P Vandenberghe; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

2.  Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites?

Authors:  Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04       Impact factor: 9.236

3.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

Authors:  G Jerusalem; Y Beguin; M F Fassotte; F Najjar; P Paulus; P Rigo; G Fillet
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

4.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.

Authors:  W A Weber; K Ott; K Becker; H J Dittler; H Helmberger; N E Avril; G Meisetschläger; R Busch; J R Siewert; M Schwaiger; U Fink
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

5.  Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy.

Authors:  Ryuji Nakamura; Toya Obara; Shigehiko Katsuragawa; Yoshiharu Tamakawa; Keisuke Koeda; Kenichiroh Ikeda; Nobuhiro Sato; Kaoru Ishida; Masanori Shozushima
Journal:  Radiat Med       Date:  2002 Jul-Aug

Review 6.  18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation.

Authors:  Hongming Zhuang; Abass Alavi
Journal:  Semin Nucl Med       Date:  2002-01       Impact factor: 4.446

7.  Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer.

Authors:  Carolyn E Reed; David H Harpole; Katherine E Posther; Sandra L Woolson; Robert J Downey; Bryan F Meyers; Robert T Heelan; Homer A MacApinlac; Sin-Ho Jung; Gerard A Silvestri; Barry A Siegel; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 5.209

8.  FDG-PET in staging lung cancer: how does it change the algorithm?

Authors:  A F T Verhagen; G P Bootsma; V C G Tjan-Heijnen; G J van der Wilt; A L Cox; M H J Brouwer; F H M Corstens; W J G Oyen
Journal:  Lung Cancer       Date:  2004-05       Impact factor: 5.705

Review 9.  PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.

Authors:  Lale Kostakoglu; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

10.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.

Authors:  A R Feinstein; D M Sosin; C K Wells
Journal:  N Engl J Med       Date:  1985-06-20       Impact factor: 91.245
View more
  3 in total

Review 1.  Personalized versus evidence-based medicine with PET-based imaging.

Authors:  Sandip Basu
Journal:  Nat Rev Clin Oncol       Date:  2010-08-10       Impact factor: 66.675

2.  [The Will Rogers phenomenon and its impact on imaging diagnostics].

Authors:  W A Golder
Journal:  Radiologe       Date:  2009-04       Impact factor: 0.635

3.  Pancreas cancer survival in the gemcitabine era.

Authors:  Mitchell S Wachtel; K Tom Xu; Yan Zhang; Maurizio Chiriva-Internati; Eldo E Frezza
Journal:  Clin Med Oncol       Date:  2008-04-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.